According to uniQure's latest financial reports the company has $0.61 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $0.61 B | 75.12% |
2022-12-31 | $0.35 B | -36.57% |
2021-12-31 | $0.55 B | 127.11% |
2020-12-31 | $0.24 B | -35.17% |
2019-12-31 | $0.37 B | 60.83% |
2018-12-31 | $0.23 B | 47.39% |
2017-12-31 | $0.15 B | 20.28% |
2016-12-31 | $0.13 B | -40.22% |
2015-12-31 | $0.22 B | 242.46% |
2014-12-31 | $64.71 M | 96.83% |
2013-12-31 | $32.87 M | 9352.78% |
2012-12-31 | $0.34 M | -75.6% |
2011-12-31 | $1.42 M | -94% |
2010-12-31 | $23.75 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Amgen AMGN | $10.94 B | 1,671.18% | ๐บ๐ธ USA |
Sanofi SNY | $9.92 B | 1,506.78% | ๐ซ๐ท France |
Sangamo Therapeutics
SGMO | $81 M | -86.89% | ๐บ๐ธ USA |
bluebird bio
BLUE | $0.17 B | -71.79% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $1.07 B | 73.79% | ๐บ๐ธ USA |
Avidity Biosciences RNA | $0.59 B | -3.65% | ๐บ๐ธ USA |